Catherine joined the Rannard group in October 2017 to develop nanoformulations of novel antiretrovirals for oral and injectable delivery for the treatment of HIV. Catherine has worked on a diverse range of analytical projects from chondritic meteorites to alkali-activated waste materials as cement replacements. She obtained an MSc in Environmental Analysis and Assessment and an MSci in Geology before studying for a PhD on nanomedicine techniques to enable the development of parenterally-administered therapeutic candidates. Catherine started working for the Centre of Excellence for long-acting Therapeutics (CELT) as part of the Unitaid-funded LONGEVITY project working on an injectable cure for hepatitis C

​